View More Recent Stories
-
Roivant Sciences (ROIV) Provides Update on Graves’ Disease Development Program
-
Here's the list of biotech stocks that have key data catalysts in 2025
-
Piper Sandler Reiterates Overweight Rating on Immunovant (IMVT)
-
RBC's biotech survey shows investors more bearish vs. last time
-
Top pharma stocks to own in 2024 – Citi
